AnaptysBio Inc (GB:0HFQ)
LSE:0HFQ

AnaptysBio (0HFQ) Stock Price & Analysis

0 Followers

0HFQ Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$21.26 - $29.76
Previous Close$24.36
Volume0.00
Average Volume (3M)17.00
Market Cap
$591.02M
Enterprise Value$169.23M
Total Cash (Recent Filing)$441.24M
Total Debt (Recent Filing)$19.45M
Price to Earnings (P/E)N/A
Beta-0.18
May 09, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding27,931,028
10 Day Avg. Volume0
30 Day Avg. Volume17
Standard Deviation0.24
R-Squared0.01
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)2.28
Price to Sales (P/S)68.51
Price to Cash Flow (P/CF)48.40
P/FCF Ratio-8.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue16.45
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.61
Forecast
Price Target Upside21.10% Upside
Rating ConsensusHold
Number of Analyst Covering3


Financials

Annual

0HFQ FAQ

What was AnaptysBio Inc’s price range in the past 12 months?
AnaptysBio Inc lowest stock price was $21.26 and its highest was $29.75 in the past 12 months.
    What is AnaptysBio Inc’s market cap?
    Currently, no data Available
    When is AnaptysBio Inc’s upcoming earnings report date?
    AnaptysBio Inc’s upcoming earnings report date is May 09, 2023 which is in 38 days.
      How were AnaptysBio Inc’s earnings last quarter?
      AnaptysBio Inc released its earnings results on Mar 01, 2023. The company reported -$0.93 earnings per share for the quarter, beating the consensus estimate of -$0.957 by $0.027.
        Is AnaptysBio Inc overvalued?
        According to Wall Street analysts AnaptysBio Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does AnaptysBio Inc pay dividends?
          AnaptysBio Inc does not currently pay dividends.
          What is AnaptysBio Inc’s EPS estimate?
          AnaptysBio Inc’s EPS estimate is -$1.02.
            How many shares outstanding does AnaptysBio Inc have?
            Currently, no data Available
            What happened to AnaptysBio Inc’s price movement after its last earnings report?
            AnaptysBio Inc reported an EPS of -$0.93 in its last earnings report, beating expectations of -$0.957. Following the earnings report the stock price went same 0%.
              Which hedge fund is a major shareholder of AnaptysBio Inc?
              Among the largest hedge funds holding AnaptysBio Inc’s share is Deerfield Management Company, LP. It holds AnaptysBio Inc’s shares valued at 36M.

                ---

                AnaptysBio Stock Smart Score

                The AnaptysBio Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                AnaptysBio Inc

                AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its pipeline includes ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

                ---

                Forecast EPS vs Actual EPS


                Similar Stocks
                Company
                Price & Change
                Follow
                Design Therapeutics
                Seres Therapeutics
                IDEAYA Biosciences
                Gossamer Bio
                Agenus

                Popular Stocks

                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis